Tamara Isakova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7067472/publications.pdf

Version: 2024-02-01

236925 182427 2,777 67 25 51 citations h-index g-index papers 67 67 67 3787 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Ten-Year Risk-Prediction Equations for Incident Heart Failure Hospitalizations in Chronic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort Study and the Multi-Ethnic Study of Atherosclerosis. Journal of Cardiac Failure, 2022, 28, 540-550.	1.7	10
2	Deoxycholic Acid and Risks of Cardiovascular Events, ESKD, and Mortality in CKD: The CRIC Study. Kidney Medicine, 2022, 4, 100387.	2.0	8
3	Abnormalities in Cardiac Structure and Function among Individuals with CKD: The COMBINE Trial. Kidney360, 2022, 3, 258-268.	2.1	5
4	A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial. Pediatric Nephrology, 2022, 37, 2547-2557.	1.7	1
5	Shared Decision Making Among Older Adults With Advanced CKD. American Journal of Kidney Diseases, 2022, 80, 599-609.	1.9	15
6	Deoxycholic Acid and Coronary Artery Calcification in the Chronic Renal Insufficiency Cohort. Journal of the American Heart Association, 2022, 11, e022891.	3.7	2
7	A Klotho-Derived Peptide as a Possible Novel Drug to Prevent Kidney Fibrosis. American Journal of Kidney Diseases, 2022, 80, 285-288.	1.9	5
8	Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction. Journal of Cardiac Failure, 2021, 27, 309-317.	1.7	9
9	Variability in Kidney Function Estimates in Emerging Adults With Spina Bifida: Implications for Transitioning From Pediatric to Adult Care. Urology, 2021, 148, 306-313.	1.0	3
10	Mineral bone disease in autosomal dominant polycystic kidney disease. Kidney International, 2021, 99, 977-985.	5.2	16
11	Subtyping CKD Patients by Consensus Clustering: The Chronic Renal Insufficiency Cohort (CRIC) Study. Journal of the American Society of Nephrology: JASN, 2021, 32, 639-653.	6.1	41
12	Hospitalization Trajectories and Risks of ESKD and Death in Individuals With CKD. Kidney International Reports, 2021, 6, 1592-1602.	0.8	6
13	Diagnostic Test Characteristics of Ultrasound Based Hydronephrosis in Identifying Low Kidney Function in Young Patients with Spina Bifida: A Retrospective Cohort Study. Journal of Urology, 2021, 205, 1180-1188.	0.4	7
14	Advance Care Planning in Older Adults with CKD: Patient, Care Partner, and Clinician Perspectives. Journal of the American Society of Nephrology: JASN, 2021, 32, 1527-1535.	6.1	30
15	Design and Rationale of HiLo: A Pragmatic, Randomized Trial of Phosphate Management for Patients Receiving Maintenance Hemodialysis. American Journal of Kidney Diseases, 2021, 77, 920-930.e1.	1.9	23
16	Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease. Kidney International, 2021, 100, 1292-1302.	5.2	22
17	Editorial: A humble way forward amid hype and hope. Current Opinion in Nephrology and Hypertension, 2021, 30, 385-386.	2.0	O
18	Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease. Bone Research, 2021, 9, 35.	11.4	24

#	Article	IF	CITATIONS
19	Assessment of Health Literacy and Self-reported Readiness for Transition to Adult Care Among Adolescents and Young Adults With Spina Bifida. JAMA Network Open, 2021, 4, e2127034.	5.9	13
20	Fibroblast Growth Factor-23 and Subclinical Markers of Cardiac Dysfunction: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. American Heart Journal, 2021, 245, 10-10.	2.7	4
21	Perceptions of Telehealth vs In-Person Visits Among Older Adults With Advanced Kidney Disease, Care Partners, and Clinicians. JAMA Network Open, 2021, 4, e2137193.	5.9	65
22	Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2020, 75, 235-244.	1.9	46
23	A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 161-174.	6.1	42
24	Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study. American Journal of Kidney Diseases, 2020, 75, 908-918.	1.9	13
25	Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency. Bone, 2020, 141, 115559.	2.9	9
26	Association of Educational Attainment With Incidence of CKD in Young Adults. Kidney International Reports, 2020, 5, 2256-2263.	0.8	12
27	Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 776-783.	4.5	27
28	Editorial: New and repurposed therapeutics for mineral, stone and vascular disorders. Current Opinion in Nephrology and Hypertension, 2020, 29, 357-358.	2.0	0
29	A Simple Equation to Estimate Urinary Flow Rate Using Urine Creatinine. American Journal of Nephrology, 2020, 51, 395-400.	3.1	3
30	Fibroblast Growth Factor 23 and Risk of Hospitalization with Infection in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study. Journal of the American Society of Nephrology: JASN, 2020, 31, 1836-1846.	6.1	17
31	Racial Differences in the Associations Between Food Insecurity and Fibroblast Growth Factor 23 in the Coronary Artery Risk Development in Young Adults Study. , 2020, 30, 509-517.		10
32	Systematic integrated analysis of genetic and epigenetic variation in diabetic kidney disease. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29013-29024.	7.1	46
33	A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. Journal of the American Society of Nephrology: JASN, 2019, 30, 1495-1504.	6.1	53
34	Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD. American Journal of Kidney Diseases, 2019, 74, 771-781.	1.9	11
35	Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function inÂaÂmouse model of chronic kidney disease. Kidney International, 2019, 96, 1346-1358.	5.2	47
36	Association of Fitness With Racial Differences in Chronic Kidney Disease. American Journal of Preventive Medicine, 2019, 57, 68-76.	3.0	3

#	Article	IF	Citations
37	DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease. Bone Research, 2019, 7, 12.	11.4	57
38	Fibroblast Growth Factor 23 Trajectories in Chronic Hemodialysis Patients: Lessons from the HEMO Study. American Journal of Nephrology, 2019, 49, 263-270.	3.1	13
39	Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study. American Journal of Kidney Diseases, 2019, 73, 806-814.	1.9	58
40	Associations of Fenofibrate Therapy WithÂlncidence and Progression of CKD inÂPatients With Type 2 Diabetes. Kidney International Reports, 2019, 4, 94-102.	0.8	30
41	Fibroblast Growth Factor-23, Heart Failure Risk, and Renin–Angiotensin–Aldosterone-System Blockade in Hypertension: The MESA Study. American Journal of Hypertension, 2019, 32, 18-25.	2.0	15
42	Early Prediction of Acute Kidney Injury in Critical Care Setting Using Clinical Notes and Structured Multivariate Physiological Measurements. Studies in Health Technology and Informatics, 2019, 264, 368-372.	0.3	25
43	The phosphate bucket list. Kidney International, 2018, 93, 1033-1035.	5.2	7
44	A Patient With CKD Develops Cholestatic Liver Injury During aÂClinical Trial. Kidney International Reports, 2018, 3, 5-10.	0.8	0
45	Management of stones and bones. Current Opinion in Nephrology and Hypertension, 2018, 27, 227-228.	2.0	0
46	Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD. American Journal of Kidney Diseases, 2018, 71, 362-370.	1.9	186
47	Deoxycholic Acid, a Metabolite of Circulating Bile Acids, and Coronary Artery Vascular Calcification in CKD. American Journal of Kidney Diseases, 2018, 71, 27-34.	1.9	46
48	Multicenter Study Evaluating Intrarenal Oxygenation and Fibrosis Using Magnetic Resonance Imaging in Individuals With Advanced CKD. Kidney International Reports, 2018, 3, 1467-1472.	0.8	13
49	Sleep disordered breathing and fibroblast growth factor 23 in the Hispanic Community Health Study/Study of Latinos. Bone, 2018, 114, 278-284.	2.9	2
50	Microbiome and Cardiovascular Disease in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1598-1604.	4.5	47
51	Racial/Ethnic Differences in Left Ventricular Structure and Function in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort. American Journal of Hypertension, 2017, 30, 822-829.	2.0	13
52	Serum Phosphate and Retinal Microvascular Changes: The Multi-Ethnic Study of Atherosclerosis and the Beaver Dam Eye Study. Ophthalmic Epidemiology, 2017, 24, 371-380.	1.7	8
53	Acid Load and Phosphorus Homeostasis in CKD. American Journal of Kidney Diseases, 2017, 70, 541-550.	1.9	28
54	Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors forÂdeath in chronic kidney disease. Kidney International, 2017, 91, 711-719.	5.2	91

#	Article	IF	CITATIONS
55	KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, andÂTreatment of Chronic Kidney Disease–Mineral and BoneÂDisorder (CKD-MBD). American Journal of Kidney Diseases, 2017, 70, 737-751.	1.9	257
56	Associations of FGF23 With Change in Bone Mineral Density and Fracture Risk in Older Individuals. Journal of Bone and Mineral Research, 2016, 31, 742-748.	2.8	41
57	Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3779-3786.	3.6	71
58	Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. JAMA Cardiology, 2016, 1, 548.	6.1	81
59	Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney International, 2016, 89, 135-146.	5. 2	370
60	An Introduction to PTH, Phosphate and Vitamin D: Current Issues and Concerns. Seminars in Dialysis, 2015, 28, 563-563.	1.3	3
61	Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. Journal of the American Society of Nephrology: JASN, 2015, 26, 2328-2339.	6.1	116
62	Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone, 2015, 78, 23-27.	2.9	19
63	Tip-toeing toward the finish line. Nephrology Dialysis Transplantation, 2015, 30, 1-3.	0.7	131
64	Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study. Nephrology Dialysis Transplantation, 2015, 30, 1534-1541.	0.7	11
65	Food Access, Chronic Kidney Disease, and Hypertension in the U.S American Journal of Preventive Medicine, 2015, 49, 912-920.	3.0	89
66	Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. Rheumatology, 2014, 53, 1613-1617.	1.9	10
67	Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney International, 2013, 83, 1159-1168.	5. 2	291